Trusted for the Complexities of AAV Manufacturing
Expertise, quality, and infrastructure to support today—and scale for tomorrow.
Where Proven Performance Meets Relentless Quality
Empowering leading innovators with the infrastructure, expertise, and partnership to deliver what’s next.
Our Facility for Your Needs
From research to cGMP and beyond, our facility is built to grow with you.
Relentless on Quality
At Forge, quality isn’t an add-on—it’s the foundation of everything we do.
Support From Start to Fill-Finish
Our integrated services are designed to support your therapy from early development through fill-finish.
execution
Seamless Technology Transfer
Have a locked process and need a partner for manufacturing execution? Forge offers collaborative, systematic tech transfer services backed by deep AAV expertise. With in-house process knowledge and access to a wide range of development and production scales, we’re built to support your success from transfer through execution.
dependability
Your Partner in Advanced Gene Therapy Solutions
With over 500 batches manufactured, 50+ clients, and experience across all serotypes, including novel, our proven experience in AAV manufacturing ensures your project is in capable hands.
Forge Your Path
Let’s talk about how we can manufacture your AAV program with confidence.
Hot off the Forge
-
Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership
“We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene therapy.”
-
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and modified rep/cap plasmids.
-
Muscular Dystrophy Association and Forge Biologics Announce AAV Development and Manufacturing Partnership
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon Hesterlee, Ph.D., CRO at the MDA.
-
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
Designation grants Forge’s FBX-101 therapy access to enter the Innovative Licensing and Access Pathway (ILAP).